LAVA Therapeutics (NASDAQ:LVTX) Stock Price Down 2.3%

LAVA Therapeutics (NASDAQ:LVTX)’s stock price was down 2.3% on Friday . The stock traded as low as $2.96 and last traded at $3.03. Approximately 47,453 shares changed hands during trading, a decline of 96% from the average daily volume of 1,352,372 shares. The stock had previously closed at $3.10.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of LAVA Therapeutics in a research report on Thursday, March 21st.

LAVA Therapeutics Price Performance

The company has a quick ratio of 6.62, a current ratio of 6.62 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average price is $2.92 and its 200-day moving average price is $2.04.

LAVA Therapeutics (NASDAQ:LVTX) last announced its earnings results on Wednesday, March 20th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.40). The business had revenue of $0.35 million during the quarter, compared to analyst estimates of $25.00 million. LAVA Therapeutics had a negative net margin of 620.09% and a negative return on equity of 68.54%. As a group, sell-side analysts anticipate that LAVA Therapeutics will post -1.41 EPS for the current year.

Institutional Trading of LAVA Therapeutics

An institutional investor recently bought a new position in LAVA Therapeutics stock. Pathway Financial Advisors LLC bought a new position in shares of LAVA Therapeutics (NASDAQ:LVTX) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 14,000 shares of the company’s stock, valued at approximately $47,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.